Acumen Pharmaceuticals
ABOS
73 hedge funds and large institutions have $108M invested in Acumen Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 21 reducing their positions, and 17 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 21
2% more capital invested
Capital invested by funds: $105M → $108M (+$2.19M)
0.04% more ownership
Funds ownership: 72.54% → 72.58% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 81 → 73 (-8)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
90% less call options, than puts
Call options by funds: $226K | Put options by funds: $2.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$648K |
| 2 |
Franklin Resources
San Mateo,
California
|
+$492K |
| 3 |
BlackRock
New York
|
+$469K |
| 4 |
Morgan Stanley
New York
|
+$411K |
| 5 |
Goldman Sachs
New York
|
+$257K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$844K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$534K |
| 3 |
Millennium Management
New York
|
-$324K |
| 4 |
Man Group
London,
United Kingdom
|
-$256K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$179K |
ABOS Hedge Fund Activity: Q3 2024 in Review
73 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q3 2024, worth a combined $108M — up 2.1% from $105M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ABOS and 10 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 25 added.
The largest buyer was Northern Trust, adding an estimated $648K. The largest seller was Laurion Capital Management, cutting an estimated $844K.
- 73 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q3 2024, down from 81 in Q2 2024.
- Funds reported $108M of Acumen Pharmaceuticals stock for Q3 2024, up 2.1% quarter-over-quarter.
- 10 funds opened new Acumen Pharmaceuticals positions in Q3 2024 and 17 closed out, a net change of -7 holders.
- The largest Acumen Pharmaceuticals buyer in Q3 2024 was Northern Trust, an estimated $648K added.
- The largest Acumen Pharmaceuticals seller in Q3 2024 was Laurion Capital Management, an estimated $844K sold.
Based on aggregated 13F filings for Q3 2024.